Psychedelics and mental health: reimagining care through science, insight, and compassion.
Georgios Mikellides, Marios Kyriazis
Frontiers in Pharmacology September 3, 2025 DOI: 10.3389/fphar.2025.1649929 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Keywords | Psychedelic therapy psychedelics Treatment Care Healing Transformation Potential Model Future Well-being Scientific Evidence Insight Empathy Compassion Mental health |
| Citations | 3 |
| Key points | The text contends that psychiatry is experiencing a renaissance in psychedelic research, driven by a crisis in mental health treatment efficacy, particularly for treatment-resistant conditions, and by recognition of the limitations of conventional monoaminergic antidepressants. It states that this has produced growing openness to previously fringe alternative paradigms. |
Abstract
In recent years, psychiatry has witnessed a renaissance in the investigation of psychedelic compounds, a broad class of psychoactive substances that induce altered states of consciousness, often characterized by changes in perception, mood, and cognition, which were largely shelved following regulatory crackdowns in the 1970s. The renewed interest is driven by a mounting crisis in mental health treatment efficacy, particularly for conditions labelled as treatment-resistant. As research continues to underscore the limitations of conventional monoaminergic antidepressants, there is a growing openness to alternative paradigms that were previously considered fringe (Wang and Wang 2025).
Citations in the library
Cited by 3
- Zalsupindole: A Non-Hallucinogenic Psychoplastogen Advancing Psychedelic-Inspired Therapeutics. ACS Chemical Neuroscience January 21, 2026
- Caution before canonisation: a clinical and implementation science perspective on psychedelics Frontiers in Psychiatry October 5, 2026
- Field Notes From Inner Space: Global Psychedelic Survey Participants Report Health Benefits, Personal Growth, and Life Transformations Contemporary Drug Problems April 25, 2026
Cites 20
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacology & Translational Science December 10, 2020
and 15 more in the library